Viruses are obligate intracellular parasites composed of nucleic acid surrounded by a protein capsid and sometimes an envelope. They replicate by hijacking host cell machinery. Many antiviral drugs are nucleoside analogs that inhibit viral polymerases after being phosphorylated intracellularly. Common antivirals target herpesviruses (acyclovir, ganciclovir), hepatitis B (adefovir, entecavir), influenza (amantadine, oseltamivir), and HIV (reverse transcriptase inhibitors). While effective against actively replicating virus, they do not eliminate latent infections. Host immunity also plays a key role in viral clearance.
This document discusses antiviral drugs used to treat various DNA and RNA viruses. It provides classifications of viruses based on their genome and structure. It then covers the viral replication cycles and mechanisms of different classes of antiviral drugs, including DNA polymerase inhibitors, mRNA synthesis inhibitors, immunomodulators, viral penetration/uncoating inhibitors, and release inhibitors. Specific antiviral drugs are discussed for treating infections caused by DNA viruses like herpes, hepatitis B, and cytomegalovirus as well as RNA viruses including influenza, hepatitis C, and respiratory syncytial virus. Adverse effects and mechanisms of action are provided for many of the antiviral drugs.
The document discusses various antiviral drugs used to treat viral infections. It begins by describing viruses and their replication cycles. It then classifies antiviral drugs based on their mechanisms of action and discusses individual drugs used to treat herpes viruses, influenza viruses, hepatitis viruses, cytomegalovirus, and more. Key drugs mentioned include acyclovir, valacyclovir, famciclovir for herpes, oseltamivir and zanamivir for influenza, and ganciclovir and valganciclovir for cytomegalovirus. The document provides details on the mechanisms, uses, and side effects of many commonly used antiviral medications.
Viruses are obligate intracellular parasites composed of nucleic acid surrounded by a protein capsid and sometimes an envelope. They replicate by hijacking host cell machinery. Many antiviral drugs are nucleoside analogs that inhibit viral DNA or RNA polymerase after being phosphorylated intracellularly. Common antivirals target herpesviruses (acyclovir, ganciclovir), hepatitis B (adefovir), influenza (oseltamivir), and cytomegalovirus (ganciclovir, cidofovir, foscarnet). While effective against actively replicating virus, antivirals do not eliminate latent infections and host immunity remains important for recovery.
This document discusses various antiviral drugs that target different stages of the viral lifecycle. It describes the mechanism of action, pharmacokinetics, uses, and side effects of several nucleoside analogues (acyclovir, cidofovir, famciclovir, ganciclovir), nucleotide analogues (foscarnet, ribavirin), and antisense oligonucleotides (fomivirsen) used to treat infections caused by DNA and RNA viruses like herpesviruses, influenza, hepatitis, and cytomegalovirus. The drugs inhibit viral DNA or RNA synthesis through competitive inhibition or chain termination mechanisms. Many require activation by viral or host kinases to form active triphosphate
This document discusses antiviral drugs used to treat viral infections. It begins with an introduction to viruses and their parasitism of host cells. The history of antiviral development is covered from the 1960s onwards. Viruses are classified and several antiviral drug classes are described including anti-herpes drugs like acyclovir and famciclovir, anti-retrovirals for HIV like zidovudine and lamivudine, and the non-selective antiviral interferon. Specific viruses and the doses, mechanisms, and adverse effects of antiviral treatments are outlined. The document concludes with a discussion of herpes virus classification and post-exposure prophylaxis for preventing HIV infection.
This document discusses antiviral drugs used to treat various viral infections. It begins by explaining the characteristics of viruses and stages of viral replication. It then categorizes and describes antiviral drugs for herpes, influenza, hepatitis B and C viruses. The drugs discussed include acyclovir, ganciclovir, amantadine, ribavirin, interferons, entecavir, tenofovir and newer oral antivirals for hepatitis C. The mechanisms of action, spectra, pharmacokinetics and therapeutic uses of these drugs are summarized. Adverse effects and importance of drug resistance are also mentioned.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
The document discusses various antiviral drugs, their mechanisms of action, and adverse effects. It covers antiviral drugs for herpes, HIV, hepatitis B/C, and influenza. For each class of antivirals, specific drugs are mentioned along with how they work against viruses at the molecular level and common side effects patients may experience. The stages of the viral life cycle are also outlined to show where different antiviral drugs target viruses.
This document discusses antiviral drugs used to treat various DNA and RNA viruses. It provides classifications of viruses based on their genome and structure. It then covers the viral replication cycles and mechanisms of different classes of antiviral drugs, including DNA polymerase inhibitors, mRNA synthesis inhibitors, immunomodulators, viral penetration/uncoating inhibitors, and release inhibitors. Specific antiviral drugs are discussed for treating infections caused by DNA viruses like herpes, hepatitis B, and cytomegalovirus as well as RNA viruses including influenza, hepatitis C, and respiratory syncytial virus. Adverse effects and mechanisms of action are provided for many of the antiviral drugs.
The document discusses various antiviral drugs used to treat viral infections. It begins by describing viruses and their replication cycles. It then classifies antiviral drugs based on their mechanisms of action and discusses individual drugs used to treat herpes viruses, influenza viruses, hepatitis viruses, cytomegalovirus, and more. Key drugs mentioned include acyclovir, valacyclovir, famciclovir for herpes, oseltamivir and zanamivir for influenza, and ganciclovir and valganciclovir for cytomegalovirus. The document provides details on the mechanisms, uses, and side effects of many commonly used antiviral medications.
Viruses are obligate intracellular parasites composed of nucleic acid surrounded by a protein capsid and sometimes an envelope. They replicate by hijacking host cell machinery. Many antiviral drugs are nucleoside analogs that inhibit viral DNA or RNA polymerase after being phosphorylated intracellularly. Common antivirals target herpesviruses (acyclovir, ganciclovir), hepatitis B (adefovir), influenza (oseltamivir), and cytomegalovirus (ganciclovir, cidofovir, foscarnet). While effective against actively replicating virus, antivirals do not eliminate latent infections and host immunity remains important for recovery.
This document discusses various antiviral drugs that target different stages of the viral lifecycle. It describes the mechanism of action, pharmacokinetics, uses, and side effects of several nucleoside analogues (acyclovir, cidofovir, famciclovir, ganciclovir), nucleotide analogues (foscarnet, ribavirin), and antisense oligonucleotides (fomivirsen) used to treat infections caused by DNA and RNA viruses like herpesviruses, influenza, hepatitis, and cytomegalovirus. The drugs inhibit viral DNA or RNA synthesis through competitive inhibition or chain termination mechanisms. Many require activation by viral or host kinases to form active triphosphate
This document discusses antiviral drugs used to treat viral infections. It begins with an introduction to viruses and their parasitism of host cells. The history of antiviral development is covered from the 1960s onwards. Viruses are classified and several antiviral drug classes are described including anti-herpes drugs like acyclovir and famciclovir, anti-retrovirals for HIV like zidovudine and lamivudine, and the non-selective antiviral interferon. Specific viruses and the doses, mechanisms, and adverse effects of antiviral treatments are outlined. The document concludes with a discussion of herpes virus classification and post-exposure prophylaxis for preventing HIV infection.
This document discusses antiviral drugs used to treat various viral infections. It begins by explaining the characteristics of viruses and stages of viral replication. It then categorizes and describes antiviral drugs for herpes, influenza, hepatitis B and C viruses. The drugs discussed include acyclovir, ganciclovir, amantadine, ribavirin, interferons, entecavir, tenofovir and newer oral antivirals for hepatitis C. The mechanisms of action, spectra, pharmacokinetics and therapeutic uses of these drugs are summarized. Adverse effects and importance of drug resistance are also mentioned.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
The document discusses various antiviral drugs, their mechanisms of action, and adverse effects. It covers antiviral drugs for herpes, HIV, hepatitis B/C, and influenza. For each class of antivirals, specific drugs are mentioned along with how they work against viruses at the molecular level and common side effects patients may experience. The stages of the viral life cycle are also outlined to show where different antiviral drugs target viruses.
This document discusses various classes of antiviral drugs, including their mechanisms of action, pharmacokinetics, therapeutic uses, and adverse effects. It describes DNA and RNA polymerase inhibitors such as acyclovir, ganciclovir, and ribavirin which work by inhibiting viral replication. It also covers adamantane derivatives amantadine and rimantidine which inhibit influenza virus uncoating, as well as neuraminidase inhibitors oseltamivir and zanamivir which prevent viral spread. Immunomodulators like interferons are also summarized, which activate the immune system against viruses.
Viruses are obligate intracellular parasites that use host cell machinery to replicate. They consist of DNA or RNA enclosed in a protein capsid. Current antiviral drugs target viruses like HIV, hepatitis B/C, herpes, influenza and RSV. These include nucleoside/non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, and integrase inhibitors used in HAART for HIV. Specific drugs like acyclovir inhibit viral DNA polymerase. Zidovudine is a nucleoside reverse transcriptase inhibitor used to treat HIV that competitively inhibits viral DNA chain elongation.
The document discusses various antiviral drugs, their mechanisms of action, and their uses. It describes nucleoside reverse transcriptase inhibitors (NRTI) like zidovudine, didanosine, zalcitabine, and lamivudine which work by competing for incorporation into viral DNA and terminating the chain. It also discusses protease inhibitors like saquinavir, indinavir, and ritonavir which prevent viral replication by binding to viral proteases and blocking protein cleavage. Finally, it mentions other antivirals like amantadine, rimantadine, acyclovir, and gancyclovir which interfere with viral attachment, uncoating, or nucleic acid replication
Viruses are obligate intracellular parasites.Our arsenal of antivirals is dangerously small.Currently available antivirals are mainly against Herpes,Hepatitis and AIDS viruses.The treatment of HCV has shifted away from the use of Peg-IFN towards oral antivirals.Preventive vaccination is the key to global control of viral infections.
This document provides information on antiviral drugs, including their mechanisms of action and examples of major drugs used to treat different viral infections. It discusses how antiviral drugs work by blocking viral penetration, inhibiting viral DNA or RNA polymerase, or inhibiting reverse transcriptase. Major antiviral drugs mentioned include acyclovir, ganciclovir, foscarnet for herpes viruses, amantadine and rimantadine for influenza, entecavir and adefovir for hepatitis B, and various nucleoside and nucleotide reverse transcriptase inhibitors as well as protease inhibitors for HIV. The document also reviews the adverse effects and guidelines for use of these various antiviral agents.
This document summarizes various anti-viral agents, including nucleoside analogs that inhibit viral DNA polymerase and reverse transcriptase. It discusses idoxuridine, trifluridine, acyclovir and other nucleoside analogs used to treat herpes viruses. It also covers reverse transcriptase inhibitors like zidovudine and didanosine used to treat HIV. Newer agents for HIV include protease inhibitors, entry inhibitors, integrase inhibitors and combination antiretroviral therapy, which is most effective at preventing drug resistance.
This document summarizes the life cycle of DNA and RNA viruses like HIV. It discusses the stages of attachment, entry, uncoating, replication, transcription, translation, assembly, maturation and egress/release. It then focuses on HIV and inhibitors that target different stages of the viral life cycle, including uncoating inhibitors, nucleoside analogues like acyclovir and zidovudine, non-nucleoside reverse transcriptase inhibitors like efavirenz, and protease inhibitors like ritonavir.
This PPT covers Drug therapy for Viral Infection or disease. It includes Viral replication cycle, classification of antiviral drugs, Anti-Herpes drug, Anti Influenza drugs, Anti hepatitis drugs and anti retroviral drugs
This document discusses various antiviral drugs used to treat different viral infections. It begins by classifying antiviral drugs into categories based on the virus they target, such as anti-herpes viruses like acyclovir and valacyclovir, anti-influenza viruses like amantadine and oseltamivir, anti-hepatitis viruses/nonselective drugs like lamivudine and ribavirin, and anti-retroviruses used to treat HIV. It then provides more details on the mechanism of action, pharmacokinetics, uses, and side effects of representative drugs from each category.
The document discusses anti-viral chemotherapy and considerations for developing effective anti-viral drugs. It notes that ideal drugs are selectively toxic to virus-infected cells, inhibit specific viral enzymes or functions, and have a high therapeutic index. Several classes of anti-viral drugs are described including nucleoside analogs that target viral polymerases, protease inhibitors for HIV, and neuraminidase inhibitors for influenza. Developing drugs that can interfere with viral replication without harming host cells remains an ongoing challenge.
This document provides information on antiviral and antiretroviral drugs. It begins by describing viruses and their replication processes. It then discusses several important viruses and the diseases they cause. The document outlines the mechanisms of replication for DNA, RNA, and retroviruses. It proceeds to classify antiviral drugs according to their therapeutic uses and mechanisms of action. Several specific antiviral and antiretroviral drugs are described in detail, including their mechanisms of action, pharmacokinetics, and side effects. The human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are also discussed.
This document provides an overview of viruses and antiviral drugs. It discusses that viruses contain nucleic acid and proteins and live inside host cells. It also categorizes major DNA and RNA viruses that infect humans. The document then describes the mechanisms of several classes of antiviral drugs, including nucleoside analogs, protease inhibitors, and drugs that inhibit viral penetration. It provides examples like acyclovir, ganciclovir, ribavirin, amantadine, and oseltamivir, and discusses their mechanisms of action, spectra of activity, clinical uses, and adverse effects.
Antiviral drugs work by interfering with the viral life cycle in various ways such as inhibiting viral nucleic acid synthesis, regulation, or the virus's ability to bind to and enter cells. There are several classes of antiviral drugs that target specific viruses including anti-herpes drugs like acyclovir and famciclovir, anti-influenza drugs like amantadine and oseltamivir, anti-hepatitis drugs like ribavirin and adefovir, and anti-HIV drugs like zidovudine, lamivudine, and interferon alpha. Many antiviral drugs are prodrugs that require activation within cells by viral or cellular enzymes
This document provides information on the history and properties of viruses. It discusses how viruses infect host cells by attaching, releasing genes/enzymes, replicating components, assembling, and releasing new viral particles. Common human viruses and the diseases they cause are listed. Properties, mechanisms of action, uses and side effects of various antiviral drugs are described, including drugs for influenza, herpes, HIV, and hepatitis viruses. Nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors used in HIV treatment are also outlined.
This document summarizes various aspects of antiviral drugs, including their classification, mechanisms of action, and use for specific viruses. It discusses drugs that target DNA viruses like herpes simplex virus and hepatitis B virus. These include nucleoside analogues like acyclovir and ganciclovir that inhibit viral DNA polymerase. It also covers drugs for influenza viruses like amantadine and oseltamivir that inhibit the viral M2 protein and neuraminidase enzyme. Antivirals for hepatitis C virus and human immunodeficiency virus are also outlined, such as interferons, ribavirin, protease inhibitors, and integrase inhibitors. The document provides brief descriptions of each drug's mechanism, pharmac
Viruses are obligate intracellular parasites that rely on host cell synthetic processes for replication. Effective antiviral agents must block viral entry/exit from cells or be active inside host cells. They inhibit virus-specific replication events or preferentially inhibit virus-directed nucleic acid or protein synthesis over host-directed synthesis. Targets include viral DNA/RNA synthesis and structural/enzymatic proteins. Common antiviral drug classes inhibit viral entry, reverse transcription, protease activity, and more. Side effects depend on drug class but can include liver toxicity, hematological abnormalities, and more.
This document summarizes antiviral drugs used to treat various viral infections. It discusses how viruses replicate inside host cells and highlights challenges in treating viral infections. It classifies antiviral drugs and describes their mechanisms of action, spectra, uses and limitations. Key drugs discussed include acyclovir for herpes viruses, ganciclovir for cytomegalovirus, oseltamivir for influenza, lamivudine/entecavir for hepatitis B, ribavirin for hepatitis C and respiratory syncytial virus, and interferons for hepatitis B and C. Adverse effects and pharmacokinetics of several drugs are also summarized.
This document summarizes antiviral drugs, including their classifications, mechanisms of action, uses, and adverse effects. It discusses several individual antiviral drugs that work by inhibiting viral attachment, uncoating, reverse transcription, nucleic acid synthesis, and release of progeny viruses. Common side effects of antiviral drugs include renal toxicity, myelosuppression, and gastrointestinal intolerance. The document provides details on antivirals for influenza, hepatitis, herpes viruses, cytomegalovirus, and human immunodeficiency virus.
Antiviral drugs are a class of medications used to treat viral infections by inhibiting the replication or growth of viruses in the body. These drugs work by targeting specific components of a virus, such as the viral enzymes, proteins, or nucleic acids, and disrupting their ability to infect or replicate inside host cells. This can help reduce the severity of symptoms, prevent complications, and speed up recovery.
There are many types of antiviral drugs available, including:
1. Nucleoside or nucleotide analogues: These drugs mimic the structure of the nucleosides or nucleotides needed for viral replication, thereby interfering with virus replication.
2. Protease inhibitors: These drugs block the activity of viral proteases, which are enzymes that are required for the replication and assembly of some viruses.
3. Interferons: These drugs are naturally occurring proteins that help the immune system fight viral infections by boosting the body's antiviral response.
4. Neuraminidase inhibitors: These drugs block the activity of viral neuraminidase, an enzyme that is required for the release of virus particles from infected cells.
5. Fusion inhibitors: These drugs block the fusion of viral and host cell membranes, which is an essential step in viral entry and replication.
Antiviral drugs can be used to treat a variety of viral infections, including influenza, HIV/AIDS, hepatitis B and C, herpes, and Ebola. However, the effectiveness of these drugs can vary depending on the specific virus and the stage of infection. Antiviral drugs may also have side effects, and it is important to consult with a healthcare provider before taking them.
This document summarizes different classes of antiviral drugs, including their mechanisms of action, pharmacokinetics, uses, and side effects. It discusses drugs that target herpes viruses like acyclovir and valacyclovir, influenza viruses like amantadine and oseltamivir, hepatitis viruses like lamivudine and ribavirin, and HIV like reverse transcriptase inhibitors and protease inhibitors. The document provides details on how these drugs inhibit virus replication through various mechanisms and their clinical applications and safety profiles.
This document discusses various classes of antiviral drugs, including their mechanisms of action, pharmacokinetics, therapeutic uses, and adverse effects. It describes DNA and RNA polymerase inhibitors such as acyclovir, ganciclovir, and ribavirin which work by inhibiting viral replication. It also covers adamantane derivatives amantadine and rimantidine which inhibit influenza virus uncoating, as well as neuraminidase inhibitors oseltamivir and zanamivir which prevent viral spread. Immunomodulators like interferons are also summarized, which activate the immune system against viruses.
Viruses are obligate intracellular parasites that use host cell machinery to replicate. They consist of DNA or RNA enclosed in a protein capsid. Current antiviral drugs target viruses like HIV, hepatitis B/C, herpes, influenza and RSV. These include nucleoside/non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, and integrase inhibitors used in HAART for HIV. Specific drugs like acyclovir inhibit viral DNA polymerase. Zidovudine is a nucleoside reverse transcriptase inhibitor used to treat HIV that competitively inhibits viral DNA chain elongation.
The document discusses various antiviral drugs, their mechanisms of action, and their uses. It describes nucleoside reverse transcriptase inhibitors (NRTI) like zidovudine, didanosine, zalcitabine, and lamivudine which work by competing for incorporation into viral DNA and terminating the chain. It also discusses protease inhibitors like saquinavir, indinavir, and ritonavir which prevent viral replication by binding to viral proteases and blocking protein cleavage. Finally, it mentions other antivirals like amantadine, rimantadine, acyclovir, and gancyclovir which interfere with viral attachment, uncoating, or nucleic acid replication
Viruses are obligate intracellular parasites.Our arsenal of antivirals is dangerously small.Currently available antivirals are mainly against Herpes,Hepatitis and AIDS viruses.The treatment of HCV has shifted away from the use of Peg-IFN towards oral antivirals.Preventive vaccination is the key to global control of viral infections.
This document provides information on antiviral drugs, including their mechanisms of action and examples of major drugs used to treat different viral infections. It discusses how antiviral drugs work by blocking viral penetration, inhibiting viral DNA or RNA polymerase, or inhibiting reverse transcriptase. Major antiviral drugs mentioned include acyclovir, ganciclovir, foscarnet for herpes viruses, amantadine and rimantadine for influenza, entecavir and adefovir for hepatitis B, and various nucleoside and nucleotide reverse transcriptase inhibitors as well as protease inhibitors for HIV. The document also reviews the adverse effects and guidelines for use of these various antiviral agents.
This document summarizes various anti-viral agents, including nucleoside analogs that inhibit viral DNA polymerase and reverse transcriptase. It discusses idoxuridine, trifluridine, acyclovir and other nucleoside analogs used to treat herpes viruses. It also covers reverse transcriptase inhibitors like zidovudine and didanosine used to treat HIV. Newer agents for HIV include protease inhibitors, entry inhibitors, integrase inhibitors and combination antiretroviral therapy, which is most effective at preventing drug resistance.
This document summarizes the life cycle of DNA and RNA viruses like HIV. It discusses the stages of attachment, entry, uncoating, replication, transcription, translation, assembly, maturation and egress/release. It then focuses on HIV and inhibitors that target different stages of the viral life cycle, including uncoating inhibitors, nucleoside analogues like acyclovir and zidovudine, non-nucleoside reverse transcriptase inhibitors like efavirenz, and protease inhibitors like ritonavir.
This PPT covers Drug therapy for Viral Infection or disease. It includes Viral replication cycle, classification of antiviral drugs, Anti-Herpes drug, Anti Influenza drugs, Anti hepatitis drugs and anti retroviral drugs
This document discusses various antiviral drugs used to treat different viral infections. It begins by classifying antiviral drugs into categories based on the virus they target, such as anti-herpes viruses like acyclovir and valacyclovir, anti-influenza viruses like amantadine and oseltamivir, anti-hepatitis viruses/nonselective drugs like lamivudine and ribavirin, and anti-retroviruses used to treat HIV. It then provides more details on the mechanism of action, pharmacokinetics, uses, and side effects of representative drugs from each category.
The document discusses anti-viral chemotherapy and considerations for developing effective anti-viral drugs. It notes that ideal drugs are selectively toxic to virus-infected cells, inhibit specific viral enzymes or functions, and have a high therapeutic index. Several classes of anti-viral drugs are described including nucleoside analogs that target viral polymerases, protease inhibitors for HIV, and neuraminidase inhibitors for influenza. Developing drugs that can interfere with viral replication without harming host cells remains an ongoing challenge.
This document provides information on antiviral and antiretroviral drugs. It begins by describing viruses and their replication processes. It then discusses several important viruses and the diseases they cause. The document outlines the mechanisms of replication for DNA, RNA, and retroviruses. It proceeds to classify antiviral drugs according to their therapeutic uses and mechanisms of action. Several specific antiviral and antiretroviral drugs are described in detail, including their mechanisms of action, pharmacokinetics, and side effects. The human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are also discussed.
This document provides an overview of viruses and antiviral drugs. It discusses that viruses contain nucleic acid and proteins and live inside host cells. It also categorizes major DNA and RNA viruses that infect humans. The document then describes the mechanisms of several classes of antiviral drugs, including nucleoside analogs, protease inhibitors, and drugs that inhibit viral penetration. It provides examples like acyclovir, ganciclovir, ribavirin, amantadine, and oseltamivir, and discusses their mechanisms of action, spectra of activity, clinical uses, and adverse effects.
Antiviral drugs work by interfering with the viral life cycle in various ways such as inhibiting viral nucleic acid synthesis, regulation, or the virus's ability to bind to and enter cells. There are several classes of antiviral drugs that target specific viruses including anti-herpes drugs like acyclovir and famciclovir, anti-influenza drugs like amantadine and oseltamivir, anti-hepatitis drugs like ribavirin and adefovir, and anti-HIV drugs like zidovudine, lamivudine, and interferon alpha. Many antiviral drugs are prodrugs that require activation within cells by viral or cellular enzymes
This document provides information on the history and properties of viruses. It discusses how viruses infect host cells by attaching, releasing genes/enzymes, replicating components, assembling, and releasing new viral particles. Common human viruses and the diseases they cause are listed. Properties, mechanisms of action, uses and side effects of various antiviral drugs are described, including drugs for influenza, herpes, HIV, and hepatitis viruses. Nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors used in HIV treatment are also outlined.
This document summarizes various aspects of antiviral drugs, including their classification, mechanisms of action, and use for specific viruses. It discusses drugs that target DNA viruses like herpes simplex virus and hepatitis B virus. These include nucleoside analogues like acyclovir and ganciclovir that inhibit viral DNA polymerase. It also covers drugs for influenza viruses like amantadine and oseltamivir that inhibit the viral M2 protein and neuraminidase enzyme. Antivirals for hepatitis C virus and human immunodeficiency virus are also outlined, such as interferons, ribavirin, protease inhibitors, and integrase inhibitors. The document provides brief descriptions of each drug's mechanism, pharmac
Viruses are obligate intracellular parasites that rely on host cell synthetic processes for replication. Effective antiviral agents must block viral entry/exit from cells or be active inside host cells. They inhibit virus-specific replication events or preferentially inhibit virus-directed nucleic acid or protein synthesis over host-directed synthesis. Targets include viral DNA/RNA synthesis and structural/enzymatic proteins. Common antiviral drug classes inhibit viral entry, reverse transcription, protease activity, and more. Side effects depend on drug class but can include liver toxicity, hematological abnormalities, and more.
This document summarizes antiviral drugs used to treat various viral infections. It discusses how viruses replicate inside host cells and highlights challenges in treating viral infections. It classifies antiviral drugs and describes their mechanisms of action, spectra, uses and limitations. Key drugs discussed include acyclovir for herpes viruses, ganciclovir for cytomegalovirus, oseltamivir for influenza, lamivudine/entecavir for hepatitis B, ribavirin for hepatitis C and respiratory syncytial virus, and interferons for hepatitis B and C. Adverse effects and pharmacokinetics of several drugs are also summarized.
This document summarizes antiviral drugs, including their classifications, mechanisms of action, uses, and adverse effects. It discusses several individual antiviral drugs that work by inhibiting viral attachment, uncoating, reverse transcription, nucleic acid synthesis, and release of progeny viruses. Common side effects of antiviral drugs include renal toxicity, myelosuppression, and gastrointestinal intolerance. The document provides details on antivirals for influenza, hepatitis, herpes viruses, cytomegalovirus, and human immunodeficiency virus.
Antiviral drugs are a class of medications used to treat viral infections by inhibiting the replication or growth of viruses in the body. These drugs work by targeting specific components of a virus, such as the viral enzymes, proteins, or nucleic acids, and disrupting their ability to infect or replicate inside host cells. This can help reduce the severity of symptoms, prevent complications, and speed up recovery.
There are many types of antiviral drugs available, including:
1. Nucleoside or nucleotide analogues: These drugs mimic the structure of the nucleosides or nucleotides needed for viral replication, thereby interfering with virus replication.
2. Protease inhibitors: These drugs block the activity of viral proteases, which are enzymes that are required for the replication and assembly of some viruses.
3. Interferons: These drugs are naturally occurring proteins that help the immune system fight viral infections by boosting the body's antiviral response.
4. Neuraminidase inhibitors: These drugs block the activity of viral neuraminidase, an enzyme that is required for the release of virus particles from infected cells.
5. Fusion inhibitors: These drugs block the fusion of viral and host cell membranes, which is an essential step in viral entry and replication.
Antiviral drugs can be used to treat a variety of viral infections, including influenza, HIV/AIDS, hepatitis B and C, herpes, and Ebola. However, the effectiveness of these drugs can vary depending on the specific virus and the stage of infection. Antiviral drugs may also have side effects, and it is important to consult with a healthcare provider before taking them.
This document summarizes different classes of antiviral drugs, including their mechanisms of action, pharmacokinetics, uses, and side effects. It discusses drugs that target herpes viruses like acyclovir and valacyclovir, influenza viruses like amantadine and oseltamivir, hepatitis viruses like lamivudine and ribavirin, and HIV like reverse transcriptase inhibitors and protease inhibitors. The document provides details on how these drugs inhibit virus replication through various mechanisms and their clinical applications and safety profiles.
Viruses are the smallest infectious agents consisting of genetic material surrounded by a protein coat. They cannot reproduce on their own and must infect a host cell. There are DNA and RNA viruses that cause various diseases. Antiviral drugs target different stages of the viral life cycle, including entry, replication, assembly and release. Examples discussed include nucleoside/non-nucleoside reverse transcriptase inhibitors for HIV, and amantadine/oseltamivir for influenza which interfere with viral uncoating and neuraminidase activity respectively. Interferons are endogenous proteins with broad-spectrum antiviral effects. Acyclovir targets herpes viruses by incorporating into viral DNA. Effective antiviral treatment requires combinations of drugs to prevent
This document discusses various classes of antiviral drugs, including those that target herpes viruses, influenza virus, hepatitis viruses, and HIV. It provides details on the mechanism of action, pharmacokinetics, uses, and adverse effects of representative drugs in each class, such as acyclovir for herpes, amantadine/rimantadine for influenza, lamivudine/adefovir for hepatitis B, ribavirin/interferon for hepatitis C, and zidovudine as the prototype nucleoside reverse transcriptase inhibitor for HIV. The goal of antiviral treatment is to inhibit virus-specific replication events while minimizing effects on host cell processes.
The document discusses anti-viral drugs used to treat various viral infections such as HIV, hepatitis, herpes and influenza. It describes the classification, mechanism of action, dosing and side effects of various nucleoside analogues, protease inhibitors and other drugs. The summary of treatment of HIV includes the goals of combination antiretroviral therapy to suppress viral replication and prevent drug resistance in order to prolong life and improve quality of life for patients.
TREATMENT OF RESPIRATORY VIRUS INFECTIONS
A.Neuraminidase inhibitors
NAIs block the release of the influenza virus from infected host cells and thus reduce the spread of infection in the respiratory tract.
B.Inhibitors of viral uncoating
amantadine and rimantad are example of drug for viral uncoating inhibitors
the drugs effective in both treatment and prevention
Ribavirin
Ribavirin is a synthetic guanosine analog.
It is effective against a broad spectrum of RNA and DNA viruses.
. Lamivudine This cytosine analog
is an inhibitor of both hepatitis B virus (HBV) DNA polymerase and human immunodeficiency virus (HIV) reverse transcriptase.
. Adefovir dipivoxil is a nucleotide analog that is phosphorylated to adefovir diphosphate , which is
Herpes viruses are associated with diseases like cold sores and genital infections. There are several drugs that are effective against these viruses during acute infection, including acyclovir, cidofovir, foscarnet, ganciclovir, penciclovir/famciclovir, and trifluridine. These drugs work by incorporating into viral DNA or inhibiting viral polymerases. Highly active antiretroviral therapy (HAART) uses combinations of drugs from five classes to suppress HIV replication, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, entry inhibitors, and integra
pharmacology of Antiviral Agents final.pptNorhanKhaled15
Viral replication consists of several steps that can be targeted by antiviral agents. Acyclovir and related drugs like valacyclovir and famciclovir inhibit herpes virus replication through phosphorylation within infected cells and inhibition of viral DNA polymerase. Foscarnet inhibits viral DNA and RNA polymerases without requiring phosphorylation. Ganciclovir and cidofovir also inhibit viral polymerases after intracellular phosphorylation. Antiretroviral drugs used to treat HIV include nucleoside analog reverse transcriptase inhibitors like zidovudine, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors which inhibit viral enzymes and replication at different stages of the viral life cycle.
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.
This document discusses various classes of antiviral drugs and examples within each class. It covers:
1) Agents for treating herpes simplex virus and varicella zoster virus like acyclovir which require phosphorylation to become activated.
2) Agents for treating cytomegalovirus like ganciclovir which is activated similarly to acyclovir but has different pharmacokinetics.
3) Antiretroviral agents used to treat HIV/AIDS that target different stages of the viral lifecycle such as reverse transcriptase inhibitors and protease inhibitors.
This document provides information on HIV/AIDS including:
- HIV is a retrovirus that causes AIDS by infecting CD4 cells. It can be managed but not cured.
- AIDS is the late stage of HIV infection when the immune system is severely damaged.
- The natural history of the virus is described from its discovery in 1981 through treatments developed.
- The virus's structure and life cycle involve invading cells and integrating its DNA for dormancy.
- Transmission occurs through bodily fluids like blood, semen, breastmilk. Testing and treatment can control spread.
This document discusses the pharmacology of various antiviral drugs. It begins by explaining the life cycle of viruses and how antivirals work to inhibit viral replication. The optimal properties of antivirals are then outlined. Several classes of antivirals are described including those for herpes, hepatitis, HIV, and influenza. The mechanisms of specific antiviral drugs like acyclovir, valacyclovir, protease inhibitors, and neuraminidase inhibitors are summarized. Adverse effects and considerations for use are also mentioned.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
Most antiviral drugs target viral replication by interfering with viral nucleic acid synthesis or late protein synthesis. They require conversion to active triphosphate forms by host cell kinases to inhibit viral polymerases more selectively than host polymerases. Combination antiviral therapy increases effectiveness and delays drug resistance emergence. Current HIV treatment involves two or three drugs before symptoms, often two reverse transcriptase inhibitors plus a protease inhibitor to slow viral load increases and delay resistance.
The document discusses anti-viral drugs, their mechanisms of action, spectra, pharmacokinetics and therapeutic uses. It describes how certain drugs like acyclovir are selectively activated within virus infected cells. Common classes include purine/pyrimidine analogs which inhibit viral DNA polymerase, and prodrugs requiring phosphorylation. Anti-virals inhibit active viral replication but do not eliminate non-replicating virus. Effective treatment depends on inhibitory drug concentrations at infection sites.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects and pharmacokinetics of many of these drugs are also summarized.
This document summarizes various anti-viral and anti-fungal agents. It discusses the mechanism of action and clinical uses of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, lamivudine, emtricitabine and others for treating HIV. It also covers anti-herpes drugs like acyclovir, valacyclovir, famciclovir and penciclovir; anti-CMV drugs like ganciclovir and cidofovir; and other agents for treating hepatitis, influenza and fungal infections. The adverse effects, pharmacokinetics and mechanisms of these different classes of drugs are summarized.
medicinal chemistry of Antiviral drugsFatenAlsadek
medicinal chemistry of antiviral drugs with its chemical structures and how they chemically work
Done by: Faten Al-Sadek , Pharmacy student at Mohammed Al-Mana college for Health Sciences -MACHS
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
2. Viruses are made up of core genome of
nucleic acid contained in a protein shell
called Capsid
Surrounded by lipoprotein membrane called
envelope (Genome + Capsid + Envelope = Virion)
Viruses are obligate intracellular parasite ie.
do not have a metabolic machinery of their
own – uses host enzymes
10/5/2013 2
3. • Certain viruses multiply in the cytoplasm
but others do in the nucleus
• Some viruses have unique enzymes for
DNA/RNA synthesis or protein cutting
in virus assembly.
• Most multiplication take place before
diagnosis is made
10/5/2013 3
4. • DNA viruses
• Adenoviruses (upper respiratory infections)
• Herpes simplex (genital herpes)
• Hepadna virus (hepatitis B)
• Cytomegalovirus (CMV)
• Varicella (chickenpox) and varicella-zoster
• Smallpox
• RNA viruses : Influenza A and B
• RNA retroviruses : Human immunodeficiency virus (HIV)
10/5/2013 4
5. Adsorption to and penetration of
susceptible cells.
Synthesis of early, nonstructural proteins.
Synthesis of RNA or DNA.
Synthesis of late, structural proteins
Assembly of viral particles and release
10/5/2013 5
9. Many antiviral drugs are Purine or
Pyrimidine analogs.
Many antiviral drugs are Prodrugs.
They must be phosphorylated by viral or
cellular enzymes in order to become
active.
Anti-viral agents inhibits active replication
The viral growth resumes after drug
removal.
10/5/2013 9
10. Current anti-viral agents do not eliminate
non-replicating or latent virus
Effective host immune response remains
essential for the recovery from the viral
infection
Clinical efficacy depends on achieving
inhibitory conc. at the site of infection
within the infected cells
10/5/2013 10
14. • Valacyclovir is a prodrug of Acyclovir with
better bioavailability.
• Famciclovir is hydrolyzed to Penciclovir and
has greatest bioavailability.
• Penciclovir is used only topically whereas
Famciclovir can be administered orally.
• All are guanine nucleoside analogs.
10/5/2013 14
16. 1. Taken up by cells
2. Converted by viral and cellualr enzymes to the
triphosphate form
3. The triphosphate form inhibits:
• DNA polymerase
• Reverse transcriptase
• RNA polymerase
4. Or it may get incorporated into growing DNA
leading to abnormal proteins or breakage.
10/5/2013 16
17. A Guanine analogue with antiviral for Herpes group only
Acyclovir AcycloGMP AcycloGTP
Thymidine kinase Cellular kinases
Viral 200x affinity
of mammalian
1. Inhibits viral DNA polymerase selectively
2. Incorporated into DNA and terminates synthesis
10/5/2013
DR RAHUL KUNKULOL 17
18. Active against
HSV-1 (Labial and
ocular infection)
HSV-2 (Genital
infection)
Varicella-zoster
infections
Epstein barr virus
Resistance :
HSV and varicella
zoster
Deficiency in
thymidine kinase
activity
Changes in virus
directed enzymes
10/5/2013
DR RAHUL KUNKULOL 18
20. • Primary disease :
• Acyclovir 5% ointment 6 times a day for 10
days
• Late & severe cases: 400 mg TDS orally for
10 days
• Recurrent disease:
• Iv infusion 5mg/kg over 1 hr repeated 8 hrly
for 10 days
• Followed by suppressive treatment with oral
acyclovir
10/5/2013 20
21. 10/5/2013 21
• Mucocutaneous :
• Remains localized to lips and gums
(Acyclovir skin cream)
• H.Simplex encephalitis
• 10 mg /kg /8hr iv acyclovir for 10 days
• H. Simplex keratitis (HSV–I)
• Acyclovir eye ointment 5 times a day for
3days
24. • Mechanism like Acyclovir
• Active against all Herpes viruses including
CMV
• Low oral bioavailability given I.V.
• Drug of choice for CMV infections:
retinitis, pneumonia, colitis…
10/5/2013 24
25. Bone marrow suppression
(leukopenia 40%, thrombocytopenia 20%)
CNS effects
(headache, behavioral, psychosis, coma,
convulsions)
1/3 of patients have to stop because of adverse
effects
10/5/2013 25
27. Approved for the treatment of CMV retinitis in
immunocompromised patients
Nucleoside analog of cytosine
Gets converted to only cidofovir diphosphate
and inhibit viral DNA polymerase
It inhibits viral DNA synthesis
Available for IV, Intravitreal inj, Topical
Nephrotoxicity is a major disadvantage.
Uses : CMV retinitis
10/5/2013 27
28. Adenosine analogue
Converted by cellular kinases to active diphosphate
Inhibits Hepatitis B virus DNA polymerase
Gets incorporated into DNA causes Chain
termination
Use: Chronic hepatitis B
AE : Nephrotoxicity, lactic acidosis,
hepatomegaly.
10/5/2013 28
29. Adenine nucleoside analogue
Convert to Ara-A triphosphate and inhibit DNA
polymerase
Active against HSV and vaccina virus
› Treatment of HSV encephalitis and herpetic keratitis
Poor solubility, given i.v. with big volume of
fluids (2.5 L) ⇒ risk of fluid overload
10/5/2013 29
30. GI
Bone marrow
Hypokalemia
Inappropriate ADH secretion;
Psychosis; painful neuropathy;
Not a drug of choice for anything :
Replaced by Acyclovir because of toxicity and
problems in administration.
10/5/2013 30
31. • Active against HSV and VZV
• First pyrimidine analogue used as antiviral.
• It is iodinated derivative of deoxyuridine.
• MOA same as acyclovir
10/5/2013 31
32. • Topical use for treatment of HSV infections
of the eyelid, cornea and skin.
• Only indication-
Herpes simplex kerato-conjunctivitis
• High toxicity :
• Bone marrow depression
• Due to incorporation of idoxuridine into host
cell DNA
10/5/2013 32
33. • An inorganic pyrophosphate analog
• Active against Herpes (I, II), Varicella , CMV,
including those resistant to Acyclovir and
Ganciclovir.
• Direct inhibition of DNA polymerase and
RT
• Very poor oral bioavalibility so given slow iv.
10/5/2013 34
34. • CMV retinitis and other CMV infections
instead of Ganciclovir.
• H simplex resistant to Acyclovir
• H. simplex in AIDS patients
10/5/2013 35
35. • Nephrotoxicity (25%) most common ADR
• Hypocalcaemia (chelates divalent cations)
• Others: Hypokalemia,
Hypomagnesaemia
10/5/2013 36
36. Inhibit replication of both DNA and
RNA viruses
Triphosphate inhibits RNA polymerase
Anemia due to hemolysis and BM
suppression
10/5/2013 37
37. Ribavirin is the drug of choice for:
• RSV bronchiolitis and pneumonia in
hospitalized children (given by aerosol)
Ribavirin is an alternative drug for:
• Influenza, Parainfluenza, Measles virus
infection in immunocompromised
patients
10/5/2013 38
38. • Is a Oligonucleotide
• Primarily an anti CMV agent
• Binds to mRNA and inhibit synthesis of
immediate early proteins needed for
replication
• Injected intravitreally for : CMV retinitis in
patients of AIDS
• A/E: Iritis, Vitreitis.
10/5/2013 39
40. • Chemically a tricyclic amine not related to any
nucleotide
• Inhibit penetration of virus to cells ,the uncoating of
certain virus and viral replication.
• M2 protein which acts as ion channell appears to be
its one of the target.
• Prevent diseases caused by influenza A
• Treatment of Parkinson’s disease
10/5/2013 42
42. • Inhibit neuraminidase enzyme of influenza
• Enzyme essential for release of virus
• Examples: zanamivir and oseltamivir
• Zanamivir administered via inhalation
administered orally
• Oseltamivir is converted to O. carboxylate
(oral bioavalibility 80%)
10/5/2013
DR RAHUL KUNKULOL
44
43. • Therapeutic Use
• Treatment of acute uncomplicated Influenza A
(H1N1 virus, swine flu) : Oseltamivir 75mg BD
• Prevention : 75mg OD
• Adverse effects
• N/V, Bronchospasm and abnormal
respiratory function
10/5/2013 45
44. • Three classes of interferons – α , β, γ
• α and β interferons: produced by all the
cells in response to viral infections
• γ interferon : produced only by T
lymphocyte and NK cells in response to
cytokines – immune regulating effects
• γ has less anti-viral activity compared to α
and β interferon
10/5/2013 46
45. Induction of the following enzymes:
A protein kinase which inhibits protein
synthesis
An oligo-adenylate synthase which leads to
degradation of viral mRNA
A phosphodiesterase which inhibit t-RNA
The action of these enzymes leads to an
inhibition of translation
10/5/2013 47
46. • Interferon prevent spread of viruses to new cells
(Viral hepatitis)
• Natural products of the immune system in viral
infections
• Antiviral, anticancer and immuno-modulating
• Toxicity: flu-like syndrome, BM suppression; CNS
• Use :Hepatitis B and C
10/5/2013 48
48. Antivirals Spectrum
Foscarnet HSV, CMV in AIDS
Ribavirin RSV, Parainfluenza
Fomivirsen CMV retinitis in AIDS
Amantidine,
Rimantidine
Influenza A Virus
Oseltamivir H1N1 influenza
Interferon HBV, HCV
10/5/2013 50
49. Virus Diseases
Drug(s) of
choice
Alternative
drugs
Inf. A
Influenza Amantadine Rimantadine
RSV
Pneumonia,
bronchiolitis
Ribavirin
(aerosol)
HSV Genital herpes Acyclovir Foscarnet
Keratitis
Conjunctivitis
Trifluridine
Idoxuridine
Vidarabine
Encephalitis Acyclovir
Neonatal HSV
infection
Acyclovir Vidarabine
Herpes infections in
immuno-
compromised host
Acyclovir Foscarnet
10/5/2013
DR RAHUL KUNKULOL
51
50. In normal host No therapy
Immunocompromised
host, or pregnancy Acyclovir Foscarnet
CMV Retinitis Ganciclovir Foscarnet
HCV
Interferons
Hepatitis B
Hepatitis C
VZV
CMV
10/5/2013
DR RAHUL KUNKULOL
52
HBV
51. • Guanosine analogue
• Competitively inhibits viral DNA
polymerase
• Approved by FDA in march 2005 for
treatment of chronic hepatitis B
• Oral bioavailibility : 95%
• AE : Headach, fatigue, NV
10/5/2013 53
52. • Neuramidase inhibitor
• Approved in 2009
• For emergency treatment of hospitalised
patients of H1N1 infection
• Used iv for patients resistant to
Oseltamivir, zanamivir….
10/5/2013 54